Andrew Perlman
Director/Board Member at ARCUS BIOSCIENCES, INC.
Net worth: 208 061 $ as of 2024-04-29
Profile
Andrew J.
Perlman is the founder of Innate Immune, Inc. (founded in 2004) and Velocity Pharmaceutical Development LLC (founded in 2011).
He is currently the CEO, CFO, and Secretary of Spitfire Pharma, Inc., an Independent Director at Arcus Biosciences, Inc., the Managing Director and Head of Non-Clinical Development at X-37 Service Co., Inc., and an Advisor at Avestria Ventures Management, LLC.
Dr. Perlman's former positions include Chief Executive Officer and Director at Affymax, Inc. (in 2002), Senior Director of Clinical Research at Genentech, Inc., Independent Director at ISTA Pharmaceuticals, Inc. (from 2006 to 2012), Executive Vice President at Tularik, Inc. (from 1993 to 2002 and from 2002 to 2004), Venture Partner at Presidio Partners, and President at Vitesse Biologics LLC.
Dr. Perlman received his undergraduate degree from Massachusetts Institute of Technology and his doctorate from New York University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0.02% | 2024-02-29 | 14,125 ( 0.02% ) | 208 061 $ | 2024-04-29 |
Andrew Perlman active positions
| Companies | Position | Start |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Director/Board Member | 2020-12-16 |
Velocity Pharmaceutical Development LLC
 Velocity Pharmaceutical Development LLC Drugstore ChainsRetail Trade Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA. | Founder | 2010-12-31 |
Spitfire Pharma, Inc.
 Spitfire Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Spitfire Pharma, Inc. provides drug development and research services. The firm’s products include SP-1373, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis. The company was founded by John J. Nestor, Jr. and is headquartered in South San Francisco, CA. | Chief Executive Officer | - |
X-37 Service Co., Inc.
 X-37 Service Co., Inc. Miscellaneous Commercial ServicesCommercial Services X-37 Service Co., Inc. operates as a pharmaceutical discovery and development company. The firm uses advanced artificial intelligence technology to discover novel drug candidates by screening vast libraries of chemical compounds against pharmaceutical targets. It offers five development programs in areas of high medical need including cancer, autoimmune diseases, and coagulation disorders. The company was founded by David J. Collier and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Avestria Ventures Management, LLC
 Avestria Ventures Management, LLC Investment ManagersFinance Avestria Ventures Management LLC (Avestria Ventures) is a venture capital firm founded in 2018 by Linda M. Greub and Corinne H. Nevinny. The firm is headquartered in San Francisco, California. | Consultant / Advisor | - |
Former positions of Andrew Perlman
| Companies | Position | End |
|---|---|---|
Innate Immune, Inc.
 Innate Immune, Inc. Medical SpecialtiesHealth Technology Innate Immune, Inc. discovers and develops therapeutics for asthma and autoimmune diseases. The company provides services to the hospitals and health care centers. Innate Immune was founded by Andrew J. Perlman and is headquartered in Stanford, CA | Founder | - |
Vitesse Biologics LLC
 Vitesse Biologics LLC Pharmaceuticals: MajorHealth Technology Vitesse Biologics LLC develops antibody and protein-based therapeutics in the areas of immunology, hematology and oncology. The company was founded in June 2015 and is headquartered in South San Francisco, CA. | President | 2020-11-30 |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 2004-09-30 |
| AFFYMAX, INC. | Chief Executive Officer | 2002-09-30 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Andrew Perlman
| Massachusetts Institute of Technology | Undergraduate Degree |
| New York University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AFFYMAX, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Private companies | 10 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
ISTA Pharmaceuticals, Inc.
 ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Health Technology |
Innate Immune, Inc.
Innate Immune, Inc. Medical SpecialtiesHealth Technology Innate Immune, Inc. discovers and develops therapeutics for asthma and autoimmune diseases. The company provides services to the hospitals and health care centers. Innate Immune was founded by Andrew J. Perlman and is headquartered in Stanford, CA | Health Technology |
Spitfire Pharma, Inc.
Spitfire Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Spitfire Pharma, Inc. provides drug development and research services. The firm’s products include SP-1373, a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis. The company was founded by John J. Nestor, Jr. and is headquartered in South San Francisco, CA. | Commercial Services |
Presidio Partners
 Presidio Partners Investment ManagersFinance Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California. | Finance |
Velocity Pharmaceutical Development LLC
Velocity Pharmaceutical Development LLC Drugstore ChainsRetail Trade Velocity Pharmaceutical Development LLC develops pharmaceutical drugs. It identifies drug candidates, target markets and designing and managing outsourced clinical trials. The firm seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated. The company was founded by David Collier, Ed Schnipper, Jim Larrick and Andy Perlman in 2011 and is headquartered in South San Francisco, CA. | Retail Trade |
Vitesse Biologics LLC
Vitesse Biologics LLC Pharmaceuticals: MajorHealth Technology Vitesse Biologics LLC develops antibody and protein-based therapeutics in the areas of immunology, hematology and oncology. The company was founded in June 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Avestria Ventures Management, LLC
Avestria Ventures Management, LLC Investment ManagersFinance Avestria Ventures Management LLC (Avestria Ventures) is a venture capital firm founded in 2018 by Linda M. Greub and Corinne H. Nevinny. The firm is headquartered in San Francisco, California. | Finance |
X-37 Service Co., Inc.
X-37 Service Co., Inc. Miscellaneous Commercial ServicesCommercial Services X-37 Service Co., Inc. operates as a pharmaceutical discovery and development company. The firm uses advanced artificial intelligence technology to discover novel drug candidates by screening vast libraries of chemical compounds against pharmaceutical targets. It offers five development programs in areas of high medical need including cancer, autoimmune diseases, and coagulation disorders. The company was founded by David J. Collier and is headquartered in South San Francisco, CA. | Commercial Services |
- Stock Market
- Insiders
- Andrew Perlman
